Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT06123338
- Locations
- 🇺🇸
Johns Hopkins University (Data Collection Only), Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital (Data Collection Only), Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-05-03
- Target Recruit Count
- 36
- Registration Number
- NCT06109467
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Target Recruit Count
- 570
- Registration Number
- NCT06107790
- Locations
- 🇨🇳
Jiangsu Province People's Hospital (First Affiliated Hospital of Nanjing Medical University), Nanjing, Jiangsu, China
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Adrienne G. Waks
- Target Recruit Count
- 40
- Registration Number
- NCT06100874
- Locations
- 🇺🇸
DFCI @ South Shore Hospital, South Weymouth, Massachusetts, United States
🇺🇸Dana Farber Cancer Institite, Boston, Massachusetts, United States
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
- Conditions
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Isala
- Target Recruit Count
- 679
- Registration Number
- NCT06031233
- Locations
- 🇳🇱
Isala Hospital, Zwolle, Netherlands
AryoTrust® (Trastuzumab) Safety Study
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- AryoGen Pharmed Co.
- Target Recruit Count
- 597
- Registration Number
- NCT06021379
- Locations
- 🇮🇷
Hashemi Nezhad Hospital, Mashhad, Iran, Islamic Republic of
🇮🇷Imam Reza Hospital, Mashhad, Iran, Islamic Republic of
🇮🇷Shahid Fayaz-Bakhsh Hospital, Tehran, Iran, Islamic Republic of
Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 30
- Registration Number
- NCT06016387
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2023-08-18
- Target Recruit Count
- 60
- Registration Number
- NCT05997524
- Locations
- 🇧🇩
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Target Recruit Count
- 181
- Registration Number
- NCT05983094
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- wang shusen
- Target Recruit Count
- 116
- Registration Number
- NCT05978648
- Locations
- 🇨🇳
Sun-yat sen university cancer center, Guangzhou, Gangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.